XM does not provide services to residents of the United States of America.
S
S

Sobi


News

Sobi Raises 2024 Revenue Growth Outlook

BRIEF-Sobi Raises 2024 Revenue Growth Outlook July 16 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : OUTLOOK 2024: REVENUE IS ANTICIPATED TO GROW BY LOW DOUBLE-DIGIT PERCENTAGE AT CER (PREVIOUSLY HIGH SINGLE-DIGIT) OUTLOOK 2024: ADJUSTED EBITA MARGIN IS ANTICIPATED TO BE IN MID-30S PERCENTAGE OF REVENUE (UNCHANGED) Q2 EBITA WAS SEK 1,486
S

SOBI Initiates Application To FDA For Sel-212

BRIEF-SOBI Initiates Application To FDA For Sel-212 July 2 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI INITIATES ROLLING BIOLOGICS LICENSE APPLICATION TO FDA FOR SEL-212 FOR THE POTENTIAL TREATMENT OF CHRONIC REFRACTORY GOUT Source text for Eikon: ID:nWkr1p8p2x Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

European Commission Grants SOBI Marketing Authorisation For Altuvoct For Treatment Of Haemophilia A

BRIEF-European Commission Grants SOBI Marketing Authorisation For Altuvoct For Treatment Of Haemophilia A June 19 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : EUROPEAN COMMISSION GRANTS SOBI MARKETING AUTHORISATION FOR ALTUVOCT FOR TREATMENT OF HAEMOPHILIA A Source text for Eikon: ID:nPnbqb3K2a Further company coverage: SOBIV.ST (Gdans
S

Sobi's Emapalumab-Lzsg Gets FDA Fast Track Status

BRIEF-Sobi's Emapalumab-Lzsg Gets FDA Fast Track Status May 27(Reuters) - Swedish Orphan Biovitrum AB (Publ) SOBIV.ST : SAID ON FRIDAY SOBI RECEIVES US FDA FAST TRACK DESIGNATION FOR EMAPALUMAB-LZSG BEING INVESTIGATED IN MACROPHAGE ACTIVATION SYNDROME Source text for Workspace: nGNX2NyYH3 Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

Sobi Completes SEK 3 Bln Senior Bond Issue

BRIEF-Sobi Completes SEK 3 Bln Senior Bond Issue May 8 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : HAS COMPLETED SEK 3 BILLION SENIOR BOND ISSUE BOND ISSUE GENERATED STRONG INVESTOR INTEREST AND WAS OVERSUBSCRIBED Source text for Eikon: ID:nWkr7Hwzpq Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

SOBI Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa

BRIEF-SOBI Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa April 26 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI® RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF EFANESOCTOCOG ALFA FOR ONCE-WEEKLY TREATMENT OF HAEMOPHILIA A Source text for Eikon: ID:nPreJVR39a Further company coverage: SOBIV.ST
S

SOBI Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa

BRIEF-SOBI Receives Positive CHMP Opinion Recommending Approval Of Efanesoctocog Alfa April 26 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI® RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF EFANESOCTOCOG ALFA FOR ONCE-WEEKLY TREATMENT OF HAEMOPHILIA A POSITIVE OPINION WILL NOW BE SUBMITTED TO EUROPEAN COMMISSION FOR MARKET
S

SOBI Establishes MTN Programme With Framework Amount Of SEK 10 Bln

BRIEF-SOBI Establishes MTN Programme With Framework Amount Of SEK 10 Bln April 26 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : ESTABLISHES MTN PROGRAMME WITH A FRAMEWORK AMOUNT OF SEK 10 BILLION, PUBLISHES A BASE PROSPECTUS Source text for Eikon: ID:nWkr25rLvy Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

SOBI rallies after Q1 sales beat estimate

BUZZ-SOBI rallies after Q1 sales beat estimate ** Swedish Orphan Biovitrum's SOBIV.ST shares rise around 8% to their highest since early February after the pharmaceutical group's Q1 sales beat estimate s ** SOBI reported Q1 sales of SEK 6.26 billion, a beat of about 11% according to LSEG data , mostly driven by Haematology franchise sales growth of
S

Swedish Orphan Biovitrum Q1 Haematology Revenue Increased 46% YOY

BRIEF-Swedish Orphan Biovitrum Q1 Haematology Revenue Increased 46% YOY April 25 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : Q1 HAEMATOLOGY REVENUE INCREASED 46% AT CER TO SEK 4,075 M VS SEK 2,815 MLN YR AGO Q1 IMMUNOLOGY REVENUE DECREASED 11% AT CER TO SEK 1,908 M SEK 2,151 MLN YR AGO OUTLOOK 2024 UNCHANGED Source text for Eikon: ID:
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.